Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Opioid Action Plan Could Clear Califf Nomination Roadblock

This article was originally published in The Pink Sheet Daily

Executive Summary

Policy shifts to address opioid abuse epidemic include changes to immediate-release opioid labeling, updated REMS requirements, and a new advisory committee.

Advertisement

Related Content

Final Generic Abuse-Deterrent Opioids Guidance Coming This Year
Gottlieb Closing In On Confirmation Despite Senate Concern On Opioids
Gottlieb Promotes 'Bottom-Up' Review To Increase FDA Efficiency, Consistency
Opioid Policy At US FDA: Gottlieb Seeks More Activist Role To Combat Abuse
Endo’s Opana ER, Generic Oxymorphone Safety Get US FDA Panel Review
FDA’s Naloxone Product Approval Standards May See Changes
Califf Nomination Suffers 'Pile On': What Can FDA Do To Break Logjam?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079175

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel